The contract amendment lands on the site’s desk three weeks after the site initiation visit. The budget numbers have changed, not because the protocol changed, but because the trial’s external funder and the sponsor’s internal finance team could not agree on the per-patient cost structure before the SIV happened. The coordinator has already been trained. The pharmacy has already received the IP shipment. And now the site director is on the phone asking which entity actually controls the check.
That scenario is not hypothetical under the structure Johnson & Johnson announced on November 16, 2026. J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, with additional regulatory milestone payments, bringing OLN324, a VEGF/Ang2 bispecific antibody for wet AMD and DME, into J&J’s late-stage ophthalmology pipeline. Paired with that acquisition is a Blackstone deal that injects external capital to fund the Phase 3 program. When the check for a Phase 3 trial comes from a private equity life sciences vehicle rather than a sponsor’s own P&L, the operational consequences for sites start before the first patient walks in.
The Funding Structure Nobody Briefed the Site On
OLN324 is a next-generation bispecific antibody that targets both Ang-2 and VEGF-A, the same two pathways that made Genentech’s Vabysmo (faricimab-svoa), FDA-approved in January 2022, the first dual-pathway injectable approved for wet AMD and DME. J&J and Ollin say OLN324 offers advantages over Vabysmo, which puts this program squarely in a market the global anti-VEGF therapeutics market valued at $16.9 billion in 2024, with the AMD segment alone representing 48.3% of that figure. For J&J, acquiring a Phase 3-ready asset in that market makes commercial sense. For site operators, the more urgent question is who actually governs the trial budget once Blackstone’s capital enters the structure.
Blackstone Life Sciences operates on a co-development model, the firm funds defined development milestones in exchange for economics tied to those milestones. In March 2024, Blackstone committed up to $750 million to Moderna’s influenza mRNA vaccine program under a structurally similar arrangement. That model works at the portfolio level. At the site level, it introduces a governance layer that most clinical operations teams have not built into their startup SOPs. The question is not whether J&J will manage the trial professionally, they will. The question is what happens to site activation timelines and amendment cycles when budget decisions require sign-off from a capital partner who runs on a different approval cadence than a sponsor’s internal clinical operations team.
Sites running ophthalmic intravitreal injection studies already operate under tight logistics constraints. Retinal imaging equipment must be calibrated and certified before enrollment opens. Pharmacy handling protocols for intravitreal formulations require specific training and documentation. If a budget amendment arrives mid-startup because the external funder renegotiated a milestone structure, the site absorbs the delay, in coordinator hours, in pharmacy prep time, in the IRB amendment cycle if the consent form references any reimbursement structure that changes. The ICH E6(R3) expectation for sponsor oversight (section 5.0) does not distinguish between a sponsor funding its own trial and a sponsor drawing on external capital. The site sees one contract, one protocol, one contact name. The complexity behind it is invisible until a decision stalls.
What Ophthalmology Phase 3 Ops Actually Costs
Wet AMD and DME trials are among the more resource-intensive ophthalmology programs to run at the site level. Patients receiving intravitreal injections require dedicated clinical space, trained injection staff, and standardized imaging at each visit, typically BCVA testing, OCT, and fundus photography. Screen failure rates in retinal trials run high because eligibility criteria for bispecific programs often require specific lesion characteristics confirmed by central reading center review. A site that screens 10 patients to enroll 3 is absorbing real cost in imaging, coordinator time, and consent administration that standard per-patient budgets frequently undercount.
That math matters more when the trial’s budget authority sits partly outside the sponsor. Sites I work with on ophthalmic programs consistently flag two underfunded line items in their initial contracts: central reading center coordination (the administrative burden of uploading, confirming receipt, and troubleshooting imaging submissions) and screen failure reimbursement at a rate that reflects actual resource consumption. When a sponsor negotiates those budgets against an external funder’s model that prioritizes milestone efficiency, the site’s real cost of doing the trial gets compressed first.
The Blackstone structure also raises a monitoring question that site directors should ask at the PSV, not after the first monitoring visit report arrives. Under 21 CFR Part 54, sponsors must certify or disclose the financial interests of clinical investigators in covered studies. That obligation sits with the sponsor, J&J, in this case. But when trial economics are structured across a sponsor and an external capital partner, the obligation for investigator financial disclosure reviews sits with the sponsor, and sites should confirm before activation how that obligation is being managed across the sponsor and capital partner relationship. Any CRO brought in to run monitoring should have clear written agreements covering which entity’s procedures govern and which approval chain controls protocol deviation escalations.
The Activation Questions to Ask Before You Sign
For site directors evaluating an activation decision on a J&J-sponsored OLN324 trial, the PSV agenda needs two additions that do not appear on a standard visit template. First: who controls budget amendment authority, and what is the approval timeline when a site requests a contract change? If the answer involves any entity other than the sponsor’s clinical operations team, understanding the approval chain and expected timelines before the site agreement is executed is worth clarifying upfront. Second: what is the monitoring visit model, and does the oversight plan account for any audit provisions that may accompany external capital partnerships? Blackstone-style structures may carry investor audit provisions beyond standard sponsor monitoring. Sites should ask at the PSV whether any such provision exists and how it would interact with the agreed monitoring schedule.
For sponsor-side clinical operations teams inheriting an acquired asset with an external funding partner, the operational priority before site activation is a single governance document that maps every decision type (protocol amendment, budget change, SAE escalation, site termination) to a named decision-maker and a maximum response time. Ambiguity in that map does not surface during startup, it surfaces at 11 PM on a Friday when a site coordinator has an SAE to report and cannot reach the right person to confirm narrative review responsibility.
The anti-VEGF market is competitive enough that J&J cannot afford a slow Phase 3. OLN324 needs clean, well-activated sites running on schedule to build the efficacy and safety dataset that distinguishes it from Vabysmo in the eyes of a future FDA reviewer. External capital accelerates the program financially. Whether it also accelerates, or quietly complicates, the site activation timeline depends entirely on how well the clinical operations team has translated the funding structure into an operational governance model that sites can actually work with. The sites that ask those governance questions at the PSV will be the ones still enrolling when the others are renegotiating their contracts.
References
- MedCity News, “J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding”
- Vision Monday, “Johnson and Johnson to Acquire Ollin Biosciences, Advancing Retinal Disease Treatment”
- Genentech, “FDA Approves Genentech’s Vabysmo, the First and Only FDA-Approved Medicine for Both Wet AMD and DME” (January 28, 2022)
- GM Insights, “Anti-VEGF Therapeutics Market Size and Forecast, 2024”
- Blackstone, Life Sciences Funding Model and Moderna Collaboration (March 2024)
- FDA, “Financial Disclosures by Clinical Investigators” (21 CFR Part 54)
- Ollin Biosciences, “Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to Be Acquired”
